Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT00214461
First received: September 16, 2005
Last updated: April 9, 2012
Last verified: April 2012
Results First Received: March 13, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Prevention
Condition: Clostridium Infections
Interventions: Biological: Vaccine diluent buffer (Placebo)
Biological: C. difficile toxoid vaccine (2 µg)
Biological: C. difficile toxoid vaccine (10 µg)
Biological: C. difficile toxoid vaccine (50 µg)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were enrolled and treated from 01 November 2005 to 11 October 2006 in 3 medical centers in the US.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 48 participants who met the inclusion and exclusion criteria were enrolled and vaccinated.

Reporting Groups
  Description
Placebo Vaccine Group Participants who received a dose of placebo, on Days 0, 28, and 56, respectively.
Low-dose C. Difficile Vaccine Group Participants who received a dose of vaccine containing 2 µg C. difficile toxoid on Days 0, 28, and 56, respectively.
Medium-dose C. Difficile Vaccine Group Participants who received a dose of vaccine containing 10 µg C. difficile toxoid on Days 0, 28, and 56, respectively.
High-dose C. Difficile Vaccine Group Participants who received a dose of vaccine containing 50 µg, C. difficile vaccine on Days 0, 28, and 56, respectively.

Participant Flow:   Overall Study
    Placebo Vaccine Group     Low-dose C. Difficile Vaccine Group     Medium-dose C. Difficile Vaccine Group     High-dose C. Difficile Vaccine Group  
STARTED     12     12     12     12  
COMPLETED     12     12     10     11  
NOT COMPLETED     0     0     2     1  
Adverse Event                 0                 0                 1                 1  
Withdrawal by Subject                 0                 0                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Vaccine Group Participants who received a dose of placebo, on Days 0, 28, and 56, respectively.
Low-dose C. Difficile Vaccine Group Participants who received a dose of vaccine containing 2 µg C. difficile toxoid on Days 0, 28, and 56, respectively.
Medium-dose C. Difficile Vaccine Group Participants who received a dose of vaccine containing 10 µg C. difficile toxoid on Days 0, 28, and 56, respectively.
High-dose C. Difficile Vaccine Group Participants who received a dose of vaccine containing 50 µg, C. difficile vaccine on Days 0, 28, and 56, respectively.
Total Total of all reporting groups

Baseline Measures
    Placebo Vaccine Group     Low-dose C. Difficile Vaccine Group     Medium-dose C. Difficile Vaccine Group     High-dose C. Difficile Vaccine Group     Total  
Number of Participants  
[units: participants]
  12     12     12     12     48  
Age  
[units: participants]
         
<=18 years     0     0     0     0     0  
Between 18 and 65 years     0     0     0     0     0  
>=65 years     12     12     12     12     48  
Age  
[units: Years]
Mean ± Standard Deviation
  69.0  ± 3.59     72.2  ± 5.32     75.5  ± 6.47     68.9  ± 4.32     71.4  ± 5.60  
Gender  
[units: participants]
         
Female     6     8     5     7     26  
Male     6     4     7     5     22  
Region of Enrollment  
[units: participants]
         
United States     12     12     12     12     48  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants Reporting Treatment-Emergent Adverse Events Post-vaccination With Either One of Three Formulations of the Clostridium Difficile Vaccine or a Placebo Vaccine.   [ Time Frame: Day 0 to up to 70 days post first vaccination ]

2.  Secondary:   Number of Participants Achieving Seroconversion of Serum Immunoglobulin G (IgG) After Vaccination With Either a Formulation of C. Difficile Toxoid Vaccine or a Placebo Vaccine.   [ Time Frame: Day up to Day 236 post first vaccination ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Medical Director
Organization: Sanofi Pasteur Inc.
e-mail: RegistryContactUs@sanofipasteur.com


No publications provided by Sanofi

Publications automatically indexed to this study:

Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT00214461     History of Changes
Other Study ID Numbers: H-030-009
Study First Received: September 16, 2005
Results First Received: March 13, 2012
Last Updated: April 9, 2012
Health Authority: United States: Food and Drug Administration